Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.69 USD -2.09% Market Closed
Market Cap: 119B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bristol-Myers Squibb Co
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$745m
CAGR 3-Years
19%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$859m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-11%
Zoetis Inc
NYSE:ZTS
Interest Income Expense
-$176m
CAGR 3-Years
11%
CAGR 5-Years
3%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$426.9m
CAGR 3-Years
-100%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
73.25 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Interest Income Expense?
Interest Income Expense
-984m USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Interest Income Expense amounts to -984m USD.

What is Bristol-Myers Squibb Co's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-19%

Over the last year, the Interest Income Expense growth was -37%.

Back to Top